

Robert Pernecky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8129716/publications.pdf>

Version: 2024-02-01

166
papers

8,571
citations

50170

46
h-index

53109

85
g-index

181
all docs

181
docs citations

181
times ranked

12160
citing authors

#	ARTICLE	IF	CITATIONS
1	Dysfunction of the blood-brain barrier in Alzheimer's disease: Evidence from human studies. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	51
2	Risk of Late-Onset Depression and Cognitive Decline: Results From Inflammatory Proteome Analyses in a Prospective Population-Based Cohort Study. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 689-700.	0.6	11
3	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease. <i>Neuron</i> , 2022, 110, 1009-1022.e4.	3.8	27
4	Anti-Dementia Medications and Anti-Alzheimer's Disease Drugs: Side Effects, Contraindications, and Interactions. , 2022, , 1-10.		3
5	Relationship between astrocyte reactivity, using novel 11C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals. <i>Molecular Psychiatry</i> , 2022, 27, 2019-2029.	4.1	19
6	Tau deposition patterns are associated with functional connectivity in primary tauopathies. <i>Nature Communications</i> , 2022, 13, 1362.	5.8	34
7	The BDNF Val66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 614-628.	4.1	61
8	In Vivo Assessment of Neuroinflammation in α -Synuclein Tauopathies. <i>Movement Disorders</i> , 2021, 36, 883-894.	2.2	37
9	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 324-333.	1.3	19
10	Associations between APOE-, COMT Val108/158Met- and BDNF Val66Met polymorphisms and variations in depressive and anxiety symptoms, sense of coherence and vital exhaustion in the real-life setting of mandatory basic military training. <i>Journal of Neural Transmission</i> , 2021, 128, 105-114.	1.4	3
11	Persönlichkeitsstörungen im Alter. , 2021, , 319-325.		0
12	Detection Gap of Right-Asymmetric Neuronal Degeneration by CERAD Test Battery in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 611595.	1.7	2
13	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. <i>Biological Psychiatry</i> , 2021, 89, 825-835.	0.7	10
14	Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3872-3885.	3.3	22
15	Dual-Phase β -Amyloid PET Captures Neuronal Injury and Amyloidosis in Corticobasal Syndrome. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 661284.	1.7	13
16	The multidimensional beneficial effect of physical exercise on symptoms of neurocognitive disorder. <i>International Psychogeriatrics</i> , 2021, , 1-4.	0.6	0
17	Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. <i>Life</i> , 2021, 11, 484.	1.1	11
18	Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age. <i>Neurology</i> , 2021, 96, .	1.5	72

#	ARTICLE	IF	CITATIONS
19	Resting-State Network Alterations Differ between Alzheimer's Disease Atrophy Subtypes. <i>Cerebral Cortex</i> , 2021, 31, 4901-4915.	1.6	12
20	Protocol of the Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness Cohort (PRO) SubStudy. <i>BMJ Open</i> , 2021, 11, e043114.	0.8	4
21	Associations of longitudinal plasma p-tau181 and NfL with tau-PET, A β ² -PET and cognition. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1289-1295.	0.9	29
22	Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load. <i>Molecular Psychiatry</i> , 2021, 26, 5848-5855.	4.1	43
23	Cognitive reserve hypothesis in frontotemporal dementia: A FDG-PET study. <i>NeuroImage: Clinical</i> , 2021, 29, 102535.	1.4	13
24	Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. <i>Science Translational Medicine</i> , 2021, 13, eabe5640.	5.8	108
25	A microRNA signature that correlates with cognition and is a target against cognitive decline. <i>EMBO Molecular Medicine</i> , 2021, 13, e13659.	3.3	29
26	Associations between sex, body mass index, and the individual microglial response in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
27	Lifelong music practice as reserve factor: Associations with cognition and brain structure in older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
28	A residual marker of cognitive reserve modifies the cross-sectional and longitudinal association between memory and glucose hypometabolism in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
29	Longitudinal changes of phosphorylated tau 181 and neurofilament light chain in plasma and their associations with tau and amyloid PET. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
30	Evaluation of liraglutide in the treatment of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	13
31	Comparison of latent cognitive reserve markers and a latent marker score in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
32	Characterization of the NIA's Research Framework stage 2 in the longitudinal multicenter DELCODE study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
33	Gender differences in the moderating capacity of reserve and resilience factors on the association of Alzheimer's disease brain pathology and cognitive function. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
34	Feasibility of short imaging protocols for [¹⁸ F]Pi2620 tau PET in progressive supranuclear palsy. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
35	Tau spreads across connected brain regions in progressive supranuclear palsy and corticobasal syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
36	Artificial neural network visualization methods reveal diagnostically relevant brain regions to detect Alzheimer's disease: The first step towards comprehensive artificial intelligence. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
37	Prediction of amyloid-positivity in individuals with subjective cognitive decline: Machine learning approaches to optimize number-needed-to-screen. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
38	Real-space navigation testing differentiates between amyloid-positive and -negative aMCI. <i>Neurology</i> , 2020, 94, e861-e873.	1.5	24
39	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2020, 35, 595-605.	2.2	42
40	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020, 10, 12184.	1.6	4
41	Microglial activation and brain networks in Alzheimer's disease: The ActiGliA cohort study. <i>Alzheimer's and Dementia</i> , 2020, 16, e043265.	0.4	0
42	Cerebral Microhemorrhage at MRI in Mild Cognitive Impairment and Early Alzheimer Disease: Association with Tau and Amyloid β^2 at PET Imaging. <i>Radiology</i> , 2020, 296, 134-142.	3.6	10
43	Soluble TREM2 and Inflammatory Proteins in Alzheimer's Disease Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1615-1626.	1.2	29
44	Exploring causality of the association between smoking and Parkinson's disease. <i>International Journal of Epidemiology</i> , 2019, 48, 912-925.	0.9	70
45	Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 24, 101949.	1.4	14
46	Cortisol, Amyloid- β^2 , and Reserve Predicts Alzheimer's Disease Progression for Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 553-562.	1.2	20
47	Associations of Neprilysin Activity in CSF with Biomarkers for Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2019, 19, 43-50.	0.8	7
48	Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2019, 15, 1468-1477.	0.4	106
49	miRNAs Identify Shared Pathways in Alzheimer's and Parkinson's Diseases. <i>Trends in Molecular Medicine</i> , 2019, 25, 662-672.	3.5	44
50	Meta-analyses identify differentially expressed microRNAs in Parkinson's disease. <i>Annals of Neurology</i> , 2019, 85, 835-851.	2.8	84
51	Determinants of self-rated and caregiver-rated quality of life and caregiver burden in Alzheimer disease. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1378-1385.	1.3	32
52	Plasma Levels of Soluble A β^2 as a Biomarker for Alzheimer's Disease with Dementia. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 83-90.	1.2	0
53	Translational research on reserve against neurodegenerative disease: consensus report of the International Conference on Cognitive Reserve in the Dementias and the Alzheimer's Association Reserve, Resilience and Protective Factors Professional Interest Area working groups. <i>BMC Medicine</i> , 2019, 17, 47.	2.3	69
54	Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 383-394.	1.2	14

#	ARTICLE	IF	CITATIONS
55	General and abdominal adiposity and the risk of Parkinson's disease: A prospective cohort study. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 98-104.	1.1	7
56	The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort. <i>Respiratory Research</i> , 2019, 20, 257.	1.4	13
57	Alzheimer's disease pathology explains association between dementia with Lewy bodies and APOE ϵ ₄ /TOMM40 long poly ϵ T repeat allele variants. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 814-824.	1.8	14
58	CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum. <i>Neurobiology of Aging</i> , 2019, 74, 182-190.	1.5	45
59	Dementia prevention and reserve against neurodegenerative disease. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 53-60.	1.8	17
60	Dementia treatment versus prevention. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 43-51.	1.8	17
61	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. <i>Brain</i> , 2018, 141, 1186-1200.	3.7	83
62	Plasma levels of soluble amyloid precursor protein β ¹⁻² in symptomatic Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 519-524.	1.8	11
63	Fluid biomarker agreement and interrelation in dementia due to Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 193-201.	1.4	5
64	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018, 141, 2895-2907.	3.7	39
65	Cerebrospinal Fluid BACE1 Activity and sA β ¹⁻² as Biomarker Candidates of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 45, 152-161.	0.7	18
66	Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?. <i>Frontiers in Neurology</i> , 2018, 9, 483.	1.1	21
67	Soluble Amyloid Precursor Proteins in Blood: Methods and Challenges. <i>Neuromethods</i> , 2018, , 179-187.	0.2	1
68	Population-Based Approaches to Alzheimer's Disease Prevention. <i>Methods in Molecular Biology</i> , 2018, 1750, 15-29.	0.4	3
69	Metabolic connectivity for differential diagnosis of dementing disorders. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 252-262.	2.4	47
70	Prioritizing problems in and solutions to homecare safety of people with dementia: supporting carers, streamlining care. <i>BMC Geriatrics</i> , 2017, 17, 26.	1.1	13
71	Biomarkers and Functional Decline in Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 69-78.	1.2	9
72	<i>TBK1</i> Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , 2017, 38, 297-309.	1.1	87

#	ARTICLE	IF	CITATIONS
73	Nutrition for the ageing brain: Towards evidence for an optimal diet. <i>Ageing Research Reviews</i> , 2017, 35, 222-240.	5.0	161
74	Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. <i>PLoS ONE</i> , 2017, 12, e0179521.	1.1	48
75	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. <i>Health Technology Assessment</i> , 2017, 21, 1-192.	1.3	37
76	Persönlichkeitsstörungen im Alter. , 2017, , 263-269.		0
77	Is the time ripe for new diagnostic criteria of cognitive impairment due to cerebrovascular disease? Consensus report of the International Congress on Vascular Dementia working group. <i>BMC Medicine</i> , 2016, 14, 162.	2.3	30
78	Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 51.	3.0	19
79	How would a decision to leave the European Union affect medical research and health in the United Kingdom?. <i>Journal of the Royal Society of Medicine</i> , 2016, 109, 216-218.	1.1	2
80	Which medical and social decision topics are important after early diagnosis of Alzheimer's Disease from the perspectives of people with Alzheimer's Disease, spouses and professionals?. <i>BMC Research Notes</i> , 2016, 9, 149.	0.6	31
81	Plasma Proteomics Biomarkers in Alzheimer's Disease: Latest Advances and Challenges. <i>Methods in Molecular Biology</i> , 2016, 1303, 521-529.	0.4	11
82	Mapping CSF biomarker profiles onto NIA's AA guidelines for Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 587-597.	1.8	14
83	Applying Automated MR-Based Diagnostic Methods to the Memory Clinic: A Prospective Study. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 939-954.	1.2	63
84	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. <i>Neurobiology of Aging</i> , 2015, 36, 601-607.	1.5	125
85	Rare variants in β -Amyloid precursor protein (APP) and Parkinson's disease. <i>European Journal of Human Genetics</i> , 2015, 23, 1328-1333.	1.4	50
86	The role of <i>TREM2</i> R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1407-1416.	0.4	152
87	Metabolic Topology of Neurodegenerative Disorders: Influence of Cognitive and Motor Deficits. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1916-1921.	2.8	22
88	Efficient redundancy reduced subgroup discovery via quadratic programming. <i>Journal of Intelligent Information Systems</i> , 2015, 44, 271-288.	2.8	5
89	Small Vessel Disease, but Neither Amyloid Load nor Metabolic Deficit, Is Dependent on Age at Onset in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2015, 77, 704-710.	0.7	17
90	Visual Versus Semi-Quantitative Analysis of 18F-FDG-PET in Amnesic MCI: An European Alzheimer's Disease Consortium (EADC) Project. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 815-826.	1.2	67

#	ARTICLE	IF	CITATIONS
91	Gaussian Mixture Models and Model Selection for [18F] Fluorodeoxyglucose Positron Emission Tomography Classification in Alzheimer's Disease. PLoS ONE, 2015, 10, e0122731.	1.1	37
92	Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, S425-S429.e1.	0.4	35
93	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	3.9	93
94	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302
95	Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers. Trends in Molecular Medicine, 2014, 20, 8-15.	3.5	35
96	LRP-1 polymorphism is associated with global and regional amyloid load in Alzheimer's disease in humans in-vivo. NeuroImage: Clinical, 2014, 4, 411-416.	1.4	15
97	Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 684-689.	0.4	54
98	Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 553-560.	1.8	47
99	The National Institute on Aging-Alzheimer's Association research criteria for mild cognitive impairment due to Alzheimer's disease: predicting the outcome. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 325-333.	1.8	27
100	A Pan-European Study of the C9orf72 Repeat Associated with FTLD: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373.	1.1	247
101	Brain size and the compensation of Alzheimer's disease symptoms: A longitudinal cohort study. Alzheimer's and Dementia, 2013, 9, 580-586.	0.4	46
102	β -Site amyloid precursor protein-cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau. , 2013, 9, 386-391.		18
103	Metabolic Networks Underlying Cognitive Reserve in Prodromal Alzheimer Disease: A European Alzheimer Disease Consortium Project. Journal of Nuclear Medicine, 2013, 54, 894-902.	2.8	108
104	The Usefulness of Amyloid Imaging in Predicting the Clinical Outcome After Two Years in Subjects with Mild Cognitive Impairment. Current Alzheimer Research, 2013, 10, 82-85.	0.7	0
105	Guilty by Suspicion? Criminal Behavior in Frontotemporal Lobar Degeneration. Cognitive and Behavioral Neurology, 2013, 26, 73-77.	0.5	49
106	Plasma Proteomics for the Identification of Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2013, 27, 337-342.	0.6	47
107	Amyloid Cascade and Tau Pathology Cerebrospinal Fluid Markers in Mild Cognitive Impairment with regards to Alzheimer's Disease Cerebral Metabolic Signature. Journal of Alzheimer's Disease, 2013, 36, 401-408.	1.2	17
108	Reference Cluster Normalization Improves Detection of Frontotemporal Lobar Degeneration by Means of FDG-PET. PLoS ONE, 2013, 8, e55415.	1.1	25

#	ARTICLE	IF	CITATIONS
109	Niemann-Pick C Disease Gene Mutations and Age-Related Neurodegenerative Disorders. <i>PLoS ONE</i> , 2013, 8, e82879.	1.1	50
110	Dealing with uncertainty: biomarkers for the early detection of Alzheimer's disease. <i>International Psychogeriatrics</i> , 2012, 24, 1533-1535.	0.6	2
111	SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 529-534.	1.8	24
112	Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid. , 2012, 8, 304-311.		28
113	Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. <i>Neurobiology of Aging</i> , 2012, 33, 2533-2550.	1.5	108
114	White matter hyperintensities predict amyloid increase in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 2766-2773.	1.5	115
115	Asymmetric Loss of Parietal Activity Causes Spatial Bias in Prodromal and Mild Alzheimer's Disease. <i>Biological Psychiatry</i> , 2012, 71, 798-804.	0.7	20
116	Interrelations between CSF Soluble A β 1-42, Amyloid- β 1-42, SORL1, and Tau Levels in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 543-552.	1.2	21
117	Cerebrospinal Fluid BACE1 Activity and Brain Amyloid Load in Alzheimer's Disease. <i>Scientific World Journal</i> , The, 2012, 2012, 1-6.	0.8	10
118	Perfusion abnormalities in mild cognitive impairment and mild dementia in Alzheimer's disease measured by pulsed arterial spin labeling MRI. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 69-77.	1.8	103
119	Amyloid Clearance as a Treatment Target Against Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 61-73.	1.2	67
120	A Case Study of Stacked Multi-view Learning in Dementia Research. <i>Lecture Notes in Computer Science</i> , 2011, , 60-69.	1.0	3
121	Novel insights for the treatment of Alzheimer's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 373-379.	2.5	82
122	COGNITIVE RESERVE, HOMOCYSTEINE, AND COGNITION IN THE BAVARIAN SCHOOL SISTERS STUDY. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 1754-1756.	1.3	1
123	Patient Participation in Medical and Social Decisions in Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 2045-2052.	1.3	65
124	Relationship between occupation attributes and brain metabolism in frontotemporal dementia. <i>Neuropsychologia</i> , 2011, 49, 3699-3703.	0.7	34
125	Impact of SORL1 Single Nucleotide Polymorphisms on Alzheimer's Disease Cerebrospinal Fluid Markers. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 164-170.	0.7	39
126	Influence of brain-derived neurotrophic-factor and apolipoprotein E genetic variants on hippocampal volume and memory performance in healthy young adults. <i>Journal of Neural Transmission</i> , 2011, 118, 249-257.	1.4	88

#	ARTICLE	IF	CITATIONS
127	Saccadic latency in Parkinson's disease correlates with executive function and brain atrophy, but not motor severity. <i>Neurobiology of Disease</i> , 2011, 43, 79-85.	2.1	52
128	Age-related cerebral perfusion changes in the parietal and temporal lobes measured by pulsed arterial spin labeling. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 34, 1295-1302.	1.9	35
129	Molecular imaging in cognitive impairment: the relevance of cognitive reserve, importance of multisite longitudinal trials and challenges of standardised analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 399-404.	3.3	2
130	Interpreting PET scans by structured patient data: a data mining case study in dementia research. <i>Knowledge and Information Systems</i> , 2010, 24, 149-170.	2.1	15
131	Metabolic alterations associated with impaired clock drawing in Lewy body dementia. <i>Psychiatry Research - Neuroimaging</i> , 2010, 181, 85-89.	0.9	11
132	Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. <i>Molecular Psychiatry</i> , 2010, 15, 138-145.	4.1	156
133	Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ϵ 4 Genotype in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2010, 68, 879-884.	0.7	103
134	Education Attenuates the Effect of Medial Temporal Lobe Atrophy on Cognitive Function in Alzheimer's Disease: The MIRAGE Study. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 855-862.	1.2	42
135	Brain Metabolic Correlates of Cerebrospinal Fluid Beta-Amyloid 42 and Tau in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 474-480.	0.7	17
136	Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 404-417.	0.7	90
137	Impact of Alzheimers Disease on the Functional Connectivity of Spontaneous Brain Activity. <i>Current Alzheimer Research</i> , 2009, 6, 541-553.	0.7	83
138	Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: A ¹²³ I-β-CIT SPECT study. <i>Movement Disorders</i> , 2009, 24, 2097-2103.	2.2	73
139	Accelerated clinical decline in well-educated patients with frontotemporal lobar degenerations. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 362-367.	1.8	10
140	No association of TDP-43 with sporadic frontotemporal dementia. <i>Neurobiology of Aging</i> , 2009, 30, 157-159.	1.5	36
141	Right prefrontal hypometabolism predicts delusions in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2009, 30, 1420-1429.	1.5	25
142	Fluoro-Deoxy-Glucose Positron Emission Tomography Correlates of Impaired Activities of Daily Living in Dementia With Lewy Bodies: Implications for Cognitive Reserve. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 188-195.	0.6	28
143	Neurobiology of cognitive disorders. <i>Current Opinion in Psychiatry</i> , 2009, 22, 546-551.	3.1	24
144	Urinary incontinence and its functional anatomy in frontotemporal lobar degenerations. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 605-610.	3.3	37

#	ARTICLE	IF	CITATIONS
145	A 6-month, open-label study of memantine in patients with frontotemporal dementia. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 754-759.	1.3	87
146	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. <i>Neurobiology of Aging</i> , 2008, 29, 812-818.	1.5	94
147	Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. <i>NeuroImage</i> , 2008, 39, 619-633.	2.1	201
148	Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease. <i>NeuroImage</i> , 2008, 40, 1503-1515.	2.1	151
149	Interpreting PET Scans by Structured Patient Data: A Data Mining Case Study in Dementia Research. , 2008, , .		8
150	Cerebral Metabolic Dysfunction in Patients with Dementia with Lewy Bodies and Visual Hallucinations. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 531-538.	0.7	88
151	Activities of Daily Living, Cerebral Glucose Metabolism, and Cognitive Reserve in Lewy Body and Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 475-481.	0.7	34
152	Multicenter Standardized ¹⁸ F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias. <i>Journal of Nuclear Medicine</i> , 2008, 49, 390-398.	2.8	637
153	Association of the Tau Haplotype H2 With Age at Onset and Functional Alterations of Glucose Utilization in Frontotemporal Dementia. <i>American Journal of Psychiatry</i> , 2007, 164, 1577-1584.	4.0	28
154	Cerebral Metabolic Correlates of the Clinical Dementia Rating Scale in Mild Cognitive Impairment. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2007, 20, 84-88.	1.2	44
155	Metabolic Correlates of Brain Reserve in Dementia with Lewy Bodies: An FDG PET Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 416-422.	0.7	31
156	Multivariate network analysis of fiber tract integrity in Alzheimer's disease. <i>NeuroImage</i> , 2007, 34, 985-995.	2.1	162
157	Male gender is associated with greater cerebral hypometabolism in frontotemporal dementia: evidence for sex-related cognitive reserve. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 1135-1140.	1.3	38
158	Amyloid β peptide ratio 42/40 but not β 42 correlates with phospho τ in patients with low and high CSF β 40 load. <i>Journal of Neurochemistry</i> , 2007, 101, 1053-1059.	2.1	237
159	Non-fluent progressive aphasia: Cerebral metabolic patterns and brain reserve. <i>Brain Research</i> , 2007, 1133, 178-185.	1.1	40
160	Brain reserve capacity in frontotemporal dementia: a voxel-based ¹⁸ F-FDG PET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1082-1087.	3.3	42
161	Mapping Scores Onto Stages: Mini-Mental State Examination and Clinical Dementia Rating. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 139-144.	0.6	564
162	DO ALL PATIENTS WITH MILD COGNITIVE IMPAIRMENT PROGRESS TO DEMENTIA?. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1008-1010.	1.3	18

#	ARTICLE	IF	CITATIONS
163	Impairment of activities of daily living requiring memory or complex reasoning as part of the MCI syndrome. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 158-162.	1.3	198
164	Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues. <i>Age and Ageing</i> , 2006, 35, 240-245.	0.7	227
165	Progression to Dementia in Clinical Subtypes of Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 27-34.	0.7	138
166	TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. <i>Human Mutation</i> , 2005, 26, 29-35.	1.1	68